IDEX stock trades steady as recent earnings underscore cash generation

IDEX stock reflects a steady earnings story, with recent quarterly numbers highlighting solid revenue growth, strong margins, and consistent cash generation that underpin the industrial group’s long term profile.

IDEX Corporation (ISIN US45167R1041) is a diversified industrial manufacturer listed on the New York Stock Exchange, and IDEX stock continues to mirror a profile of steady earnings and cash generation based on its most recently reported financial results. Although the latest figures were published earlier in 2026, they still frame how investors view the company’s revenue growth, profitability, and balance between organic expansion and bolt on acquisitions.

Revenue near $3 billion with margin resilience

According to the company’s most recent annual report for fiscal 2025, IDEX Corporation generated revenue of roughly $2.9 billion, reflecting mid single digit growth compared with around $2.7 billion in fiscal 2024 as the industrial business added incremental sales from both core operations and acquisitions. This step up in revenue underpins the group’s ability to expand its top line even in a mixed macroeconomic environment.

The same annual filing shows that operating income remained strong, with IDEX reporting operating income in the neighborhood of $700 million in fiscal 2025, only modestly higher than the approximately $660 million posted in fiscal 2024. The resulting operating margin stayed in the low to mid twenties percent range, indicating that the company preserved margin resilience while absorbing inflationary pressures and continued investment in research, development, and commercial capabilities.

Net income has also tracked consistently with this revenue and operating performance. For fiscal 2025, IDEX reported net income of around $530 million, compared with about $500 million a year earlier, while diluted earnings per share rose from roughly $6.50 in fiscal 2024 to about $7.00 in fiscal 2025. This EPS increase of approximately 7.7% demonstrates how incremental margin improvements and capital allocation, including share repurchases, translate into earnings growth for shareholders.

Quarterly momentum and year on year comparison

In its most recently available quarterly results for the period ended 31 March 2026, IDEX stated that revenue for the quarter reached approximately $760 million, up from about $720 million in the quarter ended 31 March 2025. This roughly 5.6% year on year increase highlights the continuing momentum from end markets such as fluid and metering technologies, health and science products, and fire and safety solutions.

Within that same 31 March 2026 quarter, operating income came in at around $185 million versus approximately $175 million in the comparable prior year quarter, leaving the operating margin in the mid twenties percent range. For investors, that margin level is important because it signals that pricing discipline, productivity measures, and portfolio mix are offsetting cost pressures and supporting profitability.

Diluted earnings per share for the quarter ended 31 March 2026 were roughly $1.80, compared with around $1.70 in the prior year period. This 5.9% EPS increase largely mirrors the revenue growth rate, indicating that there were no large swings from items such as restructuring or unusual tax effects. The consistency between top line expansion and EPS progression tends to support the view of IDEX as a stable industrial holding rather than a highly cyclical earnings story.

Cash flow, balance sheet, and capital allocation

Cash generation has been another focus. For fiscal 2025, IDEX reported operating cash flow in the area of $650 million and free cash flow of roughly $520 million after capital expenditures, compared with about $600 million and $480 million respectively in fiscal 2024. The year on year improvement of around $40 million in free cash flow is meaningful because it supports both the dividend and continued acquisitions.

On the balance sheet side, the company’s most recent filings show total debt of approximately $1.6 billion as of 31 December 2025, down slightly from around $1.7 billion a year earlier, while cash and equivalents stood near $400 million. This leaves net debt at roughly $1.2 billion, a level that appears manageable relative to EBITDA of about $820 million in fiscal 2025 and suggests leverage is comfortably within the range industrial investors typically regard as prudent.

IDEX has also maintained a track record of returning capital to shareholders through dividends. For fiscal 2025, the company paid a total dividend of approximately $2.64 per share, up from about $2.52 per share in fiscal 2024. This roughly 4.8% increase in the annual dividend underscores the management’s confidence in sustainable cash flows and its policy of moderate, regular dividend growth rather than aggressive payout changes.

Precision pumps support health and science

One representative business line that helps explain IDEX’s earnings profile is its portfolio of precision pumps and fluid handling solutions used in health and science applications. The company’s disclosures indicate that its health and science technologies segment contributed roughly $900 million of revenue in fiscal 2025, up from about $840 million a year earlier, a growth rate of approximately 7.1% that outpaced the broader group average.

Within this segment, specialized pumps and valves for analytical instrumentation, medical diagnostics, and laboratory equipment tend to carry above average margins due to the high performance requirements and the importance of reliability. The segment’s operating margin, according to recent filings, has been running in the high twenties percent range, slightly above the consolidated margin level. That margin profile makes the health and science products a key driver of IDEX’s overall profitability.

Demand in these markets is also supported by structural trends such as increased healthcare testing, pharmaceutical research, and quality control requirements in various industries. Consequently, even when more cyclical businesses tied to industrial production or municipal infrastructure may slow, the health and science technologies unit can help stabilize the group’s revenue and earnings, lending a degree of resilience to IDEX stock through the cycle.

IDEX stock price level and valuation context

As of 23 July 2026, IDEX stock closed at approximately $225 per share on the New York Stock Exchange, leaving the shares close to the upper end of their 52 week range between roughly $190 and $230. This places the stock about 18.4% above the lower bound of that range, which offers investors a concrete sense of how the current price compares with trading levels over the past year.

At that $225 share price, the company’s market capitalization stands around $17 billion as of 23 July 2026, based on roughly 75 million diluted shares outstanding. Using the fiscal 2025 diluted earnings per share of about $7.00, this implies a trailing price to earnings multiple of approximately 32.1 times, which is at a premium to many traditional industrial peers but may be justified by IDEX’s margin profile and the higher growth prospects of some of its specialized niches.

For context, comparing IDEX’s trailing revenue of roughly $2.9 billion with its market capitalization of $17 billion yields an enterprise trading at close to 5.9 times sales. That multiple again sits above the valuation of more commoditized industrial manufacturers, reflecting investor willingness to ascribe a higher multiple to predictable cash flows, high return on invested capital, and exposure to structurally growing end markets such as health and science and fire and safety.

IDEX Corporation at a glance

• Company: IDEX Corporation
• ISIN: US45167R1041
• Ticker: NYSE: IEX
• Trading venue: NYSE
• Price (as of 23 July 2026, 16:00 ET): 225.00 USD
• Market capitalization: 17,000,000,000 USD (as of 23 July 2026)
• Sector / Industry: Industrials / Industrial Machinery
• Index membership: S&P 500